The 50th Anniversary of the Discovery of Reciprocal Translocation between Chromosome 9 and 22: The Impact on Molecular and Genomic Knowledge on Cancer
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: 20 July 2025 | Viewed by 1069
Special Issue Editors
Interests: hematologic diseases; oncobiology; oncogenetics/epigenetics; nutrition; drug resistance; DNA damage repair; cancer metabolism; targeted therapies; translational research; personalized oncology
Special Issues, Collections and Topics in MDPI journals
Interests: oncobiology; drug resistance; hematology; microRNAs; targeted therapies
Special Issues, Collections and Topics in MDPI journals
Interests: hematology; oncobiology; cellular and molecular mechanism of cancer; drug resistance; biomarkers; targeted therapies; translational research; personalized oncology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The year 2023 marks the 50th anniversary of the discovery of the reciprocal translocation between chromosomes 9 and 22 by Janet Rowley, which is responsible for the Philadelphia chromosome. Subsequent molecular analyses involving multiple laboratories have revealed that this translocation fuses the BCR gene on chromosome 22 with the ABL1 gene on chromosome 9, leading to the fusion gene BCR/ABL1. Geneticists later discovered that translocations could disrupt or dysregulate gene function depending on the chromosome breakpoints, leading to at least three BCR/ABL1 oncoproteins. These molecular rearrangements, in many cases, are the leading causes of various cancers. Besides the impact on diagnosis and prognosis, this discovery also had implications for treatment with the development of the first targeted therapy: the tyrosine kinase inhibitor imatinib. Hundreds of translocations and other mutations have now been associated with cancer, and some of them are targeted with new drugs. Researchers worldwide continue to identify new molecular rearrangements in cancer, hoping that this information will translate into new cancer treatments and novel cancer biomarkers.
This Special Issue, dedicated to Janet Rowley's work, will focus on the latest insights into the molecular and genomic knowledge on cancer and its clinical impact. Original research papers, reviews, and case studies reporting the molecular and genomic bases of cancer as well as hereditary cancer syndromes, the implications of genomic alterations on diagnosis, prognosis, and therapy monitoring, or potential therapeutic implications of molecular and genomic alterations are herein welcome.
Dr. Ana Cristina Gonçalves
Dr. Raquel Alves
Prof. Dr. Ana Bela Sarmento Ribeiro
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer genomics
- cancer biomarkers
- cancer pathogenesis
- precision oncology
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
